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Abstract: Toxoplasma retinochoroiditis in pregnancy may create considerable patient anxiety 
and is a dilemma for the treating ophthalmologist. A case report highlighting this clinical issue 
is presented followed by a review of the literature. Consensus in relation to the management of 
toxoplasma retinochoroiditis in pregnancy is lacking and is discussed.
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Case report
A 31-year-old immunocompetent female in the 9th week of her first pregnancy attended 
the emergency eye clinic with a one-week history of painless blurred vision in the 
right eye.
Previous ocular history included right toxoplasma retinochoroiditis when aged 
11 years, and an episode of undiagnosed blurred vision in the same eye three years 
previously. She was otherwise in good general health.
On examination, best-corrected visual acuity was 6/18 RE and 6/6 LE. There was no 
ciliary injection in the right eye. 3+ cells with keratitic precipitates were present in the 
right anterior chamber. Posterior synechiae were absent. 1+ vitreous cells with vitreous 
veils were present. Fundoscopy showed a raised pale ‘satellite lesion’ at the right macula 
with three adjacent chorioretinal scars. The optic disc was mildly swollen (Figure 1). An 
inactive scar was also evident in the temporal fundus of the left eye (Figure 2).
We diagnosed recurrent ocular toxoplasmosis with macular involvement. Investiga-
tions at presentation included negative toxoplasma immunoglobulin M (IgM).
The patient was treated with intensive topical steroid and a mydriatic only, avoid-
ing the use of systemic antimicrobial and steroid medications. The obstetric team 
maintained close surveillance on the pregnancy. Over the next few months, there was 
gradual clinical improvement and the topical steroids were slowly tapered. At 22 weeks 
of gestation, visual acuity had improved to 6/9 RE. The intraocular inflammation had 
settled and the retinal lesion appeared flatter with the edges starting to pigment. Five 
months after first presentation, the retinal lesion had become quiescent and visual 
acuity was 6/6.
Discussion
Toxoplasmosis is caused by the obligate intracellular protozoan Toxoplasma gondii.
Recurrent ocular disease is a common cause of posterior uveitis and may be sight-
threatening, particularly if lesions involve the macula or severe intraocular inflammation Clinical Ophthalmology 2009:3 658
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is present. Immunocompetent patients usually have only one 
focus of active retinal disease. The retinitis usually resolves 
by two months, although associated intraocular inflammation 
may take longer.1 The process underlying reactivation of the 
parasite in the retina is not known.
Pregnancy may create a change in the hormonal or immu-
nological environment of the mother that favours reactivation 
of ocular toxoplasmosis.2,3 Bosch-Driesden and colleagues 
reported that seven (9%) of 82 women with ocular toxoplas-
mosis developed recurrences during pregnancy.4 Reports are 
conflicting as to whether or not pregnancy is associated with 
more aggressive recurrences.3,5
It is accepted that primary infection in healthy women 
or reactivated infection in immunocompromised women can 
result in transplacental transmission if not treated, result-
ing in congenital toxoplasmosis.6 Systemic treatment has 
been shown to decrease the rate of transmission as well as 
the incidence of congenital toxoplasmosis.7 Management 
of such clinical scenarios is therefore more defined, and 
the use of toxic treatments more justifiable. Furthermore, 
most ophthalmologists would consider systemic treatment 
(including aggressive efforts with multiple therapy) in immu-
nocompetent patients with ocular toxoplasmosis presenting 
with lesions involving the macula or in close proximity to 
the optic disc.
However, reactivation of toxoplasma retinochoroiditis 
threatening vision during the first trimester of pregnancy in 
a healthy female presents a difficult management problem. 
This view is supported by the results of a US survey of 
457 ophthalmologists in which almost 25% of retinal 
subspecialists and 40% of general ophthalmologists were “not 
sure” how they would manage a pregnant patient with recur-
rent ocular toxoplasmosis and normal immune function.8
We reviewed the published evidence so that we could 
determine an optimal management strategy and, at the same 
time, provide the patient with information to address her 
concerns about any increased risk to both her own health 
and that of her unborn child from treatment or nontreatment. 
We found the published studies fell broadly into three main 
categories: (1) clinical and laboratory diagnosis to support or 
preclude intervention, (2) the risk of fetal infection associated 
with reactivated ocular toxoplasmosis in the mother, and 
(3) the risk of not treating the mother vs potential teratogenicity 
associated with some antitoxoplasma agents. The literature 
review was based on comprehensive Medline and Embase 
searches generating references on ocular toxoplasmosis 
published predominantly in the last 20 years.
Investigations
Diagnosis of ocular toxoplasmosis is primarily based on clini-
cal findings. However, a wide spectrum of clinical features 
may be present making the distinction with other causes of 
retinochoroiditis problematic.9 In some cases, difficulty may 
exist in differentiating primary and reactivated ocular disease, 
thereby making the evaluation of the risk of transplacental 
transmission and the need for therapy difficult to assess.10
It is well accepted that the role of serological investiga-
tion in the management of ocular toxoplasmosis is limited.11 
However, serological tests may be used as supportive evi-
dence to confirm the suspected clinical diagnosis, particularly 
in complex cases. Such investigations may also be warranted 
in pregnant patients in whom there is a conflict between 
the potential benefits of treatment and the risk of treatment 
toxicity to the fetus.
Figure 1 recurrent toxoplasma retinochoroiditis.   A ‘satellite lesion’ associated 
with pre-existing retinochoroidal scars is present at the right macula. The lesion 
became inactive over a period of several weeks. The acute retinochoroiditis extended 
temporally from the fovea.
Figure 2 Inactive chorioretinal scar in temporal periphery of left eye.Clinical Ophthalmology 2009:3 659
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Serological changes in acute systemic infection include 
the presence of anti-T. gondii IgM in serum and a rising 
or significantly raised level of anti-T. gondii IgG.12 Anti-T. 
gondii IgM levels may be detectable for at least 18 months 
following acute infection.11 Detection of anti-T. gondii IgA in 
serum has also been reported to be helpful in the diagnosis of 
recently acquired infections.12 The high prevalence of anti-T. 
gondii IgG in an asymptomatic, ‘normal’ population makes 
the value of its detection somewhat limited.13
In patients with retinochoroidal reactivation, there are 
often no serological changes to aid the clinician, and the 
diagnosis is weighted on clinical examination. Peripheral 
parasitemia is typically negative, suggesting reactivation 
is localized to the eye. Invasive procedures have been used 
to determine intraocular antibody production or to detect 
T. gondii DNA by polymerase chain reaction (PCR) of aque-
ous or vitreous humor samples.14 However, obtaining ocular 
tissue solely for the purpose of diagnosis is not yet common 
or established practice in the UK.15
IgG dominates the intraocular antibody response against 
the parasite.16 Intraocular production of anti-T. gondii IgG 
has been more frequently noted in patients with recurrent 
than primary ocular toxoplasmosis (isolated retinal lesions 
not arising from scars). The presence of intraocular anti-T. 
gondii IgA antibodies during recurrent disease may provide 
an important additional tool.12,16 The detection of T. gondii 
DNA in aqueous or vitreous humor is more frequently found 
in patients with primary ocular toxoplasmosis than in those 
with recurrent disease.12,14
risk of fetal transmission
Ocular disease is mainly associated with the chronic phase 
of infection with T. gondii, but may also occur during the 
acute phase of systemic infection (lasting several months) 
when anti-T. gondii IgM is still detectable. During primary 
maternal toxoplasmosis, fetal infection occurs as a result 
of maternal parasitemia and subsequent involvement of the 
placenta. The first trimester is associated with the lowest rate 
of fetal transmission, but carries the greatest risk of severe 
congenital disease (ie, there is an inverse relationship).
It is generally accepted that there is no significant risk 
of transmission to the fetus where infection in the immuno-
competent mother was acquired before conception, even if 
ocular disease reactivates during pregnancy. This is likely 
because reactivation is often localised within the eye, and 
any viable organism entering the blood would be attenuated 
rapidly due to the action of serum complement activated by 
circulating antitoxoplasma IgG.
However, the possibility of risk of transmission from mother 
to child associated with infection acquired months or years prior 
to conception cannot be excluded unequivocally, albeit that this 
is likely to be a very rare occurrence.17,18 This view is based on 
a small number of case reports suggesting women with inactive 
retinal scars due to toxoplasmosis, or who were known to have 
long-standing antitoxoplasma IgG antibodies, are also at risk 
of transmitting this disease to the fetus.17,19 This finding could 
be accounted for by a down-regulation of the T-cell-mediated 
immune response that is observed during pregnancy.20 Another 
explanation put forward is that re-infection or new infection 
with a different strain of the parasite may occur.21 This has not 
been demonstrated conclusively by laboratory studies as current 
serologic tests are not subtype-specific, but suggested indirectly 
by the presence of rising titers of maternal IgG and/or IgM.17 It 
has also been suggested that maternal infection just preceding 
conception may lead to transmission, as the parasitemia may 
remain active even months after initial exposure.17
Treatment considerations
The traditional approach for the treatment of sight-threatening 
ocular toxoplasmosis is to use multiple anti-parasitic drugs 
systemically with or without corticosteroids to reduce 
retinal scarring and limit damage caused by intraocular 
inflammation.22 Vision, lesion location, lesion size, and vitre-
ous inflammatory reaction have been identified as indications 
for systemic treatment.23
There is no consensus regarding the best treatment regi-
men in nonimmunocompromised, nonpregnant patients.23,24 
(Table 1) Furthermore, it has been suggested that treatment 
may not alter the natural history of the disease, and may even 
do more harm than good.1
Unsurprisingly, therefore, the treatment of ocular 
toxoplasmosis during pregnancy creates an even greater 
challenge, as the therapeutic options are particularly limited3. 
In principle, drugs should only be prescribed in pregnancy 
if the expected benefit to the mother is thought to be greater 
than the risk to the fetus. Few if any medications are safe 
beyond all doubt, particularly in the first trimester when the 
risk of congenital malformation is greatest.
Ophthalmologists may be less willing to treat pregnant 
patients with recurrent disease due to concerns over treatment 
toxicity.8 Consideration may be given to shortening the course 
of therapy, particularly in patients whose disease responds 
rapidly to treatment, or consider monotherapy.23 The choice 
of therapy will depend on whether the maternal ocular infec-
tion is acquired or reactivated during pregnancy, and whether 
there is any evidence of congenital infection.Clinical Ophthalmology 2009:3 660
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Ophthalmologists should consult with the patient’s 
obstetrician and an infectious disease specialist before con-
sidering systemic treatment in pregnancy for ocular toxo-
plasmosis. Patients should also be informed of their options 
including the benefits and theoretical risks of anti-toxoplasma 
medical therapy during the first trimester of pregnancy.
‘Classic therapy’ for ocular toxoplasmosis com-
prises a combination of pyrimethamine, sulfadiazine, 
and prednisolone. However, pyrimethamine should be 
avoided in pregnancy due to concerns about its poten-
tial for teratogenicity, especially in the first trimester.3 
Sulphonamides should be avoided in the third trimester, 
because they compete with bilirubin for serum proteins, 
causing kernicterus.3 However, in continental Europe, both 
pyrimethamine and sulphonamides are used to treat ocular 
toxoplasmosis during pregnancy.20
Consideration should be given to the use of other anti-
microbials. Clindamycin, azithromycin and atovaquone 
have been routinely used for the treatment of nonophthal-
mic infectious diseases in pregnancy, and shown to be 
safe and effective.25–27 Clindamycin, which concentrates 
in ocular tissue and penetrates tissue cyst walls,28 and 
azithromycin29 may be effective alternative treatments 
for patients with ocular disease. It has been suggested 
that a combination of clindamycin and atovaquone, or a 
combination of clindamycin and azithromycin may be a 
safe alternative to the treatment of ocular toxoplasmosis 
in pregnant patients.3
Spiramycin, which is only available on a named patient 
basis in the UK, is also considered a safe agent and is known 
to concentrate in the placenta, reducing the risk of transpla-
cental infection in newly acquired infections.30 However, 
spiramycin is not effective for ocular disease.24
Pars plana vitrectomy may have a role in selected patients 
in removing antigenic proteins and inflammatory debris. 
Furthermore, intraocular antibiotics may be a useful alterna-
tive for pregnant patients with ocular toxoplasmosis, by reduc-
ing the risk of systemic toxicity.31 Martinez and colleagues 
reported a case of a pregnant woman in the first trimester with 
sight-threatening reactivated ocular toxoplasmosis success-
fully managed with a combination of intravitreal clindamycin 
and dexamethasone and systemic sulfadiazine.31
Summary
In conclusion, there is evidence to suggest that pregnancy 
is linked to the reactivation of ocular toxoplasmosis and 
pregnant women at risk should, therefore, be informed about 
this risk.20
Pregnant women can be reassured that vertical transmis-
sion secondary to recurrent ocular disease is likely to be a 
rare event. It has been suggested that pregnant women at risk 
are monitored every three months by screening fundoscopy, 
and their offspring then followed systemically to exclude the 
presence of congenital infection. The detection of vertical 
transmission to the fetus is not straightforward, however.20 
Regular ultrasound examination may be appropriate to look 
for evidence of fetal involvement.32
Serum antibody titers are of limited value in the confirma-
tion of suspected recurrent ocular disease, and the diagnosis 
remains heavily weighted on clinical examination. There 
may be a role for intraocular fluid sampling in complex cases 
although this is rarely performed in the UK.
Guidelines are lacking regarding the most appropriate anti-
parasitic regimens for the treatment of ocular toxoplasmosis, 
highlighting the need for larger cohort studies. It is not surpris-
ing, therefore, that the dilemma in choosing an appropriate 
treatment strategy for pregnant patients is compounded. New, 
effective ways are required to treat ocular toxoplasmosis while 
Table 1 Therapeutic regimens of choice for typical cases of ocular 
toxoplasmosisa,b
Regimenc Respondents 
in 2001 survey
Pyrimethamine/folinic acid,d sulfadiazine, 
prednisonee
23/78 (29%)
Pyrimethamine/folinic acid,d sulfadiazine, 
clindamycin, prednisonef
10/78 (13%)
sulfadiazine, clindamycin, prednisone 1/78 (1%)
Clindamycin, prednisone 8/78 (10%)
Pyrimethamine/folinic acid, TMP/sMX, 
prednisone
5/78 (6%)
Pyrimethamine,g TMP/sMX, clindamycin, 
prednisone
4/78 (5%)
Pyrimethamine/folinic acid,d sulfadiazine 3/78 (4%)
TMP/sMX, clindamycin, prednisone 3/78 (4%)
TMP/sMX, clindamycin 3/78 (4%)
TMP/sMX, prednisone 3/78 (4%)
spiramycin, prednisone 2/78 (3%)
Notes: aCopyright © 2002. Modified with permission from Holland GN, Lewis KG. 
An update on current practices in the management of ocular toxoplasmosis. Am J 
Ophthalmol.  2002;134:102–114.   A written questionnaire was distributed to all physician 
members (n = 147) of the American Uveitis society in 2001 about treatment practices 
for ocular toxoplasmosis. bA typical case was defined as an immunocompetent male 
or nonpregnant female patient with a lesion threatening the macula or optic nerve 
head, who has decreased vision but potential for full recovery of central vision. cAll 
drug combinations cited by more than one respondent in 2001 survey. dUse of folinic 
acid was mentioned by some, but not all, respondents for these regimens in the 2001 
survey. ereferred to by some clinicians as ‘classic therapy.’ freferred to by some clini-
cians as ‘quadruple therapy.’ gThe use of folinic acid was not specifically mentioned by 
respondents for this regimen.
Abbreviation:   TMP/sMX, trimethoprim-sulfamethoxazole.Clinical Ophthalmology 2009:3
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minimizing fetal toxicity to multiple drugs. In this regard, a 
combination of intravitreal and systemic therapy may be use-
ful in treating patients with recurrent ocular toxoplasmosis in 
pregnancy with sight-threatening lesions.31
In the case presented here, we chose, following consulta-
tion with the patient, not to use standard treatment despite 
the presence of a macular lesion. A good visual outcome 
was achieved. We hope that this article serves to highlight 
to ophthalmologists alternative management options when 
dealing with a more challenging case.
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